Non-Executive Director Appointments
Summary by AI BETAClose X
19 November 2025
Genus plc
("Genus" or the "Group")
Board Change: Non-Executive Director Appointments
Genus (LSE: GNS), a leading global animal genetics company, is pleased to announce the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026.
Dr Baxter has had extensive experience in people-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading University and is currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA.
Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management.
Dr Reiter is a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees.
Their appointments follow an extensive search process using an external search agency.
Commenting on the appointments, Iain Ferguson, Chair of Genus, said:
"We are delighted to welcome Celia and Bob to the Board. Celia brings a broad range of commercial and strategic experience and knowledge, as well as a detailed understanding of executive remuneration practice and reporting requirements. Bob brings substantial genetics and gene editing technology experience, and has a track record of translating scientific projects into commercial opportunities."
For further information please contact:
Genus plc Tel: +44 (0)1256 345 970
Iain Ferguson, Chair
Jorgen Kokke, Chief Executive Officer
Buchanan Burson Tel: +44 (0)207 466 5000
Charles Ryland; Toto Berger; Sophie Wills; Verity Parker
About Genus
Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Regulatory Notes
Details of any payments to be made to Celia Baxter and Bob Reiter will be disclosed in full in the Company's 2026 Directors' Remuneration Report. Any such terms will be consistent with the Company's approved Directors' Remuneration Policy.
This announcement is made in accordance with Listing Rule 6.4.6R. There are no matters to be disclosed in connection with Listing Rule 6.4.8R (2) - (6). The person responsible for making this announcement on behalf of the Group is Lucie Grant (General Counsel and Company Secretary).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 hour ago Oxford Nanopore Technologies
- 2 hours ago AVI Global Trust
- 2 hours ago LSL Property Services
- 2 hours ago Bluebird Merchant Ventures (DI)
- 3 hours ago Power Probe PLC